Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study
- 1 October 2003
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 91 (1) , 32-38
- https://doi.org/10.1016/s0090-8258(03)00413-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II studyInternational Journal of Gynecologic Cancer, 2003
- Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancerAnti-Cancer Drugs, 2002
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Advanced epithelial ovarian cancer: 1993 consensus statementsAnnals of Oncology, 1993
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- High-dose platinum for the treatment of refractory ovarian cancerGynecologic Oncology, 1981